Veracyte (NASDAQ:VCYT) Shares Gap Down – Here’s What Happened

Veracyte, Inc. (NASDAQ:VCYT)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $59.78, but opened at $48.77. Veracyte shares last traded at $45.4590, with a volume of 825,647 shares trading hands.

Veracyte News Roundup

Here are the key news stories impacting Veracyte this week:

• Positive Sentiment: Second-quarter adjusted earnings were $0.54 per share, well above the $0.43 analyst consensus and up from $0.44 a year earlier. Revenue increased 15.5% year over year to $150.3 million, exceeding estimates of roughly $144.6 million. Veracyte Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Testing revenue, Veracyte’s core business metric, rose 19% year over year to $145.7 million, outpacing total revenue growth and supporting the company’s ongoing commercial momentum. Veracyte Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised its full-year 2026 revenue outlook to $590 million-$596 million, above the approximately $585 million analyst consensus, signaling confidence in demand and execution. Veracyte Q2 Non-GAAP Earnings, Revenue Rise; 2026 Revenue Guidance Raised
• Neutral Sentiment: The earnings call and presentation emphasized the strong quarterly performance and raised revenue guidance, but investors are looking for additional evidence that growth can accelerate beyond the current outlook. Veracyte Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the earnings beat and guidance increase, coverage questioned whether Veracyte is already fully valued. The market appears to be treating the improved outlook as insufficient to justify the stock’s elevated expectations, prompting profit-taking and a sharp decline in the shares. Is Veracyte Fully Valued After Raising 2026 Revenue Guidance?

Wall Street Analysts Forecast Growth

VCYT has been the subject of several analyst reports. Guggenheim increased their price objective on Veracyte from $45.00 to $65.00 and gave the company a “buy” rating in a report on Monday, June 29th. UBS Group boosted their target price on Veracyte from $48.00 to $52.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Wolfe Research began coverage on Veracyte in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $55.00 target price on the stock. Piper Sandler initiated coverage on Veracyte in a research note on Wednesday, July 15th. They issued an “overweight” rating and a $66.00 price target for the company. Finally, Canaccord Genuity Group raised their price target on Veracyte from $42.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $57.38.

Veracyte Stock Down 23.9%

The company has a market capitalization of $3.63 billion, a price-to-earnings ratio of 41.53 and a beta of 1.93. The business’s 50-day moving average is $53.69 and its 200-day moving average is $42.29.

Veracyte (NASDAQ:VCYT) last posted its earnings results on Thursday, July 30th. The biotechnology company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.43 by $0.11. The firm had revenue of $150.32 million for the quarter, compared to analyst estimates of $144.59 million. Veracyte had a return on equity of 9.07% and a net margin of 16.25%.Veracyte’s revenue for the quarter was up 15.5% compared to the same quarter last year. During the same period last year, the company earned $0.44 earnings per share. As a group, analysts expect that Veracyte, Inc. will post 1.27 EPS for the current year.

Insider Activity at Veracyte

In related news, CAO Jonathan Wygant sold 24,000 shares of the stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $45.40, for a total value of $1,089,600.00. Following the completion of the transaction, the chief accounting officer directly owned 45,434 shares of the company’s stock, valued at approximately $2,062,703.60. This represents a 34.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Annie Mcguire sold 10,204 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $39.02, for a total transaction of $398,160.08. Following the completion of the sale, the senior vice president owned 143,708 shares of the company’s stock, valued at $5,607,486.16. This trade represents a 6.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 206,696 shares of company stock valued at $10,079,058 in the last three months. Company insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of VCYT. State Street Corp raised its stake in Veracyte by 3.8% during the fourth quarter. State Street Corp now owns 4,360,913 shares of the biotechnology company’s stock worth $183,594,000 after purchasing an additional 161,239 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Veracyte by 3.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,118,166 shares of the biotechnology company’s stock valued at $107,042,000 after buying an additional 95,664 shares during the period. First Trust Advisors LP grew its stake in shares of Veracyte by 64.9% in the 1st quarter. First Trust Advisors LP now owns 2,117,046 shares of the biotechnology company’s stock valued at $68,190,000 after buying an additional 833,543 shares during the period. Geode Capital Management LLC increased its holdings in shares of Veracyte by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,900,882 shares of the biotechnology company’s stock worth $80,039,000 after buying an additional 9,429 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Veracyte by 31.1% during the 2nd quarter. Bank of America Corp DE now owns 1,519,710 shares of the biotechnology company’s stock worth $41,078,000 after buying an additional 360,947 shares during the last quarter.

About Veracyte

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.